About | Free Trial

Last Update

2016-05-17T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Sanja Selak?

Dr. Sanja Selak

Chief Executive Officer and Scientific Affairs

Origimm Biotechnology GmbH

Direct Phone: +43 **********       

Email: s***@***.com

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Origimm Biotechnology GmbH

Background Information

Employment History

Head of Serology and Immune Assays Department (SIA)

Intercell AG

Affiliations

Postdoctoral Fellow
Instituto Cajal, CSIC

Education

PhD degree

neuroimmunology

Web References (26 Total References)


One Nucleus: Origimm e.U.

preview.onenucleus.com [cached]

Origimm was founded by Dr. Sanja Selak, the former Head of the Department of Serology and Immune Assays at Intercell in 2012.


Origimm was founded by ...

www.onenucleus.com [cached]

Origimm was founded by Dr. Sanja Selak, the former Head of the Department of Serology and Immune Assays at Intercell in 2012.


Customer Research Case Studies | ProImmune

www.proimmune.com [cached]

Sanja Selak, Intercell AG


Customer Research Case Studies | ProImmune

www.proimmune.com [cached]

Sanja Selak, Intercell AG


Developing Effective Vaccine Strategies at Intercell | ProImmune

www.proimmune.com [cached]

Dr. Sanja Selak (front row, second from left) and the Serology and Immune Assays team at Intercell AG, Austria.

Epitope discovery systems, such as ProImmune's Antigen Characterization Platform, often identify a large number of candidate epitope sequences. While many protein sequences can potentially be antigenic only a few will be relevant as key antigens with addressable immune responses in vivo. To complicate matters further, the available antigens from pathogens may alter over the course of an infection, as Dr. Sanja Selak of Intercell AG, Austria, outlined in her presentation at ProImmune's Antigen Characterization and Biomarker Discovery Summit in January 2011.
Dr. Selak is investigating the B cell epitopes of pathogenic bacteria, and their potential for use in vaccination strategies. Bacterial antigens are especially tricky to work with because bacteria do not express the same proteome consistently. They react to their environment, in particular the availability of micronutrients, and respond by expressing the cellular machinery they require to survive, so that a whole gamut of new antigens can suddenly become available. She has to consider not only the 'who' of candidate epitopes from her discovery strategies, but the 'when' 'where' and 'why', as bacteria adapt to survive in their local habitat.
...
Since animal models are of limited value with such well-adapted human pathogens, Dr. Selak and her colleagues are now beginning to consider the potential offered by tissue explant cultures for simulation of bacterial microenvironment during infection.
...
Watch and listen to a slidecast of Sanja Selak's presentation at the ProImmune Antigen Characterization and Biomarker Discovery Summit

Similar Profiles

Other People with this Name

Other people with the name Selak

Gabe Selak
San Diego History Center

Chris Selak
Lionsgate incorporated

Joy Selak
mindPOP

Wendi Selak
Alliant Insurance Services Inc

Adnan Selak
LumenData Inc

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory